Asimov, a synthetic biology company specialising in the advancement of therapeutic manufacturing, has launched its fourth generation CHO Edge System.
With an increased typical titer range of 5-11 g/L across modalities before any upstream process optimisation, the new system has been developed to optimise expression across a breadth of biologic architectures and increase the likelihood of high titre cell lines.
According to Asimov, the system is more robust, and will allow the company to increase its CLD titre guarantee for immunoglobulin G (IgG) monoclonal antibodies to 5g/L.
If the lead clone doesn’t hit this benchmark, it is still transferred to the partner, but the service fee and commercial use license fees are waived.
The 4th generation CHO Edge System updates expression vector architectures, genetic parts selection and process methodologies.
In addition, the new system incorporates a suite of AI models to predict signal peptide cleavage, RNA splicing and upstream process optimisation.
Customers can access these advanced capabilities by licensing the CHO Edge System or as part of Asimov’s Cell Line Development Service.
Alec Nielsen, co-founder and CEO of Asimov said: “Our 4th generation CHO Edge System incorporates learnings from a wide range of molecules, and an array of proprietary data-driven AI models. We have upgraded the vector architectures, genetic parts selection, and predictive modeling across multiple biological processes. While we always target titers in excess of 10 g/L in our CLD process, we can now guarantee a minimum of 5 g/L for IgG molecules. By offering a titer guarantee, we aim to set a new standard for cell line development in the industry and redefine the expectations of therapeutic developers.”
The CHO Edge System incorporates a GMP-banked CHO-K1 GS knock-out host (or a GS-Fut8 double knockout), a hyperactive transposase, a library of >1000 characterised genetic parts and advanced computational models.
Asimov reliably generates stable cell lines with high titre and product quality by using the CHO Edge System to optimise the expression vector across modalities.